These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16185567)

  • 21. Infliximab in inflammatory bowel disease: attention to adverse events.
    Uyanikoglu A; Ermis F; Akyuz F; Pinarbasi B; Baran B; Aydogan T; Demir K; Besisik F; Kaymakoglu S
    Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2337-42. PubMed ID: 25219835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study.
    Gustavsson A; Järnerot G; Hertervig E; Friis-Liby I; Blomquist L; Karlén P; Grännö C; Vilien M; Ström M; Verbaan H; Hellström PM; Magnuson A; Halfvarson J; Tysk C
    Aliment Pharmacol Ther; 2010 Oct; 32(8):984-9. PubMed ID: 20937043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuberculosis and treatment with infliximab.
    Zhang Z; Correa H; Bégué RE
    N Engl J Med; 2002 Feb; 346(8):623-6. PubMed ID: 11859880
    [No Abstract]   [Full Text] [Related]  

  • 25. Severe rosacea in a patient on infliximab for ulcerative colitis: pathophysiological considerations.
    Kosmidou M; Gaitanis G; Nomikos K; Zioga A; Katsanos K; Bassukas ID; Tsianos E
    Acta Derm Venereol; 2009; 89(5):522-3. PubMed ID: 19734983
    [No Abstract]   [Full Text] [Related]  

  • 26. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease.
    Izbéki F; Nagy F; Szepes Z; Kiss I; Lonovics J; Molnár T
    Inflamm Bowel Dis; 2008 Mar; 14(3):429-31. PubMed ID: 17973302
    [No Abstract]   [Full Text] [Related]  

  • 28. Attention to Infliximab adverse events: chimeric monoclonal antibodies can induce anti chimeric antibodies that may result in Kounis hypersensitivity associated acute coronary syndrome.
    Kounis NG; Kounis GN; Soufras GD; Tsigkas G; Hahalis G
    Eur Rev Med Pharmacol Sci; 2014; 18(24):3735-6. PubMed ID: 25555859
    [No Abstract]   [Full Text] [Related]  

  • 29. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
    Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
    Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis.
    Dumitrescu G; Dahan K; Treton X; Corcos O; Bouhnik Y; Stefanescu C
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):249-51. PubMed ID: 26114187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone.
    Parihar V; Maguire S; Shahin A; Ahmed Z; O'Sullivan M; Kennedy M; Smyth C; Farrell R
    Ir J Med Sci; 2016 Nov; 185(4):965-967. PubMed ID: 26358724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Variant of Miller Fisher Syndrome Occurring With Tumor Necrosis Factor α Antagonist Therapy.
    Ratnarajan G; Thompson A; Dodridge C; Parry A; Elston J
    JAMA Neurol; 2015 Nov; 72(11):1377-8. PubMed ID: 26551961
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist.
    Angelucci E; Cocco A; Viscido A; Vernia P; Caprilli R
    Inflamm Bowel Dis; 2007 Aug; 13(8):1059-61. PubMed ID: 17387676
    [No Abstract]   [Full Text] [Related]  

  • 36. Peripheral neuropathy with infliximab therapy in inflammatory bowel disease.
    Burger DC; Florin TH
    Inflamm Bowel Dis; 2009 Dec; 15(12):1772. PubMed ID: 19170193
    [No Abstract]   [Full Text] [Related]  

  • 37. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Motor neuropathy with multiple conduction blocks associated with TNF-alpha antagonist.
    Carrilho PE; Araújo AC; Alves O; Kotze PG
    Arq Neuropsiquiatr; 2010 Jun; 68(3):452-4. PubMed ID: 20602052
    [No Abstract]   [Full Text] [Related]  

  • 39. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thromboembolic event associated with antitumor necrosis factor-alpha treatment: report of a case.
    Miguel-Gomez L; Jimenez-Gomez N; Muñoz-Zato E; Carrillo R
    Int J Dermatol; 2016 Sep; 55(9):e501-3. PubMed ID: 26341645
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.